Lanzhou Foci Pharmaceutical Co Ltd
SZSE:002644
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lanzhou Foci Pharmaceutical Co Ltd
Operating Income
Lanzhou Foci Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lanzhou Foci Pharmaceutical Co Ltd
SZSE:002644
|
Operating Income
¥67.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥6.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Operating Income
¥7.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
35%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
Lanzhou Foci Pharmaceutical Co Ltd
Glance View
Lanzhou Foci Pharmaceutical Co., Ltd. engages in raw material research, modern formulations production, and extraction of traditional chinese medicine. The company is headquartered in Lanzhou, Gansu and currently employs 1,295 full-time employees. The company went IPO on 2011-12-22. The Company’s main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The firm distributes its products under the brand names Foci, Baolu and Mianshan. The firm is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The firm distributes its products in domestic market and to overseas markets.
See Also
What is Lanzhou Foci Pharmaceutical Co Ltd's Operating Income?
Operating Income
67.4m
CNY
Based on the financial report for Dec 31, 2025, Lanzhou Foci Pharmaceutical Co Ltd's Operating Income amounts to 67.4m CNY.
What is Lanzhou Foci Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
14%
Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for Lanzhou Foci Pharmaceutical Co Ltd have been -21% over the past three years , 3% over the past five years , and 14% over the past ten years .
